

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**STAPPER et al.**

Examiner: UNASSIGNED

Art Unit: UNASSIGNED

Application No.: NOT YET ASSIGNED

Filed: **FEBRUARY 27, 2004**

Title: **CYCLOALKYL-SUBSTITUTED  
ALKANOIC ACID DERIVATIVES,  
PROCESSES FOR THEIR PREPARATION  
AND THEIR USE AS  
PHARMACEUTICALS**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Express Mail in an envelope addressed to  
Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, on

2-27-2004

Date of Deposit

Deena Walker  
Signature

EL964832275US

Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,

Barbara E. Kurys

Barbara E. Kurys, Reg. No. 34,650  
Attorney For Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0020USNP